SCHEMBL7128982

SCHEMBL7128982

CCCCCCCC(O)C(Cl)(Cl)Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.45
SPHK1 Q9NYA1 2/20 0.45
FFAR1 O14842 2/20 0.45
LMNA P02545 2/20 0.44
CYP2D6 P10635 2/20 0.42
GMNN O75496 1/20 0.42
POLB P06746 1/20 0.42
THPO P40225 1/20 0.42
MTOR P42345 1/20 0.42
BLM P54132 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
CETP P11597 1/20 0.42
HTT P42858 1/20 0.42
UBE2N P61088 1/20 0.42
FFAR4 Q5NUL3 1/20 0.41
FDPS P14324 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1023184 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNACYP2D6
SCHEMBL7119558 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNACYP2D6
SCHEMBL20477538 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNACYP2D6
SCHEMBL7993815 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNACYP2D6
SCHEMBL7119131 0.98 GPR84 (0.41) GPR84SPHK1FFAR1LMNACYP2D6
SCHEMBL9732333 0.90 ALDH1A1 (0.37) GPR84SPHK1FFAR1LMNAFDPS
SCHEMBL30874780 0.80 GPR84 (0.48) GPR84SPHK1FFAR1LMNACYP2D6
SCHEMBL30262990 0.80 GPR84 (0.48) GPR84SPHK1FFAR1LMNACYP2D6
Ammonia Solution, Strong SCHEMBL9635696 0.79 GPR84 (0.39) GPR84SPHK1FFAR1LMNACYP2D6
Ammonia Solution, Strong SCHEMBL28834637 0.79 GPR84 (0.39) GPR84SPHK1FFAR1LMNACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109134716-B Vanadium catalyst and method for preparing olefin polymer 北京引发科技有限公司 2020-11-10 CN claimed
CN-109134716-B Vanadium catalyst and method for preparing olefin polymer 北京引发科技有限公司 2020-11-10 CN disclosed
US-20030144541-A1 Process for preparing alpha-halogenated retones RHODIA CHIMIE (FR) 2003-07-31 US disclosed
EP-1250303-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2002-10-23 EP disclosed
WO-2001055067-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2001-08-02 WO disclosed
US-5696087-A ADMINISTERING A POLYPEPTIDE OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 1997-12-09 US disclosed
US-5681819-A POLYPEPTIDE CONTAINING ATLEAST 4 ELEVEN AMINO ACID REPEAT HAVING ATLEAST THREE PROLINES PRESENT IN CARBOXY TERMINAL REGION OF HUMAN BILE SALT ACTIVATED LIPASE, THAT BINDS SPECIFIC RECEPTOR ON INTESTINAL CELL OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 1997-10-28 US disclosed
EP-0795011-A1 METHOD AND COMPOSITIONS FOR REDUCING CHOLESTEROL ABSORPTION Oklahoma Medical Research Foundation (US) 1997-09-17 EP disclosed
WO-1996017054-A1 METHOD AND COMPOSITIONS FOR REDUCING CHOLESTEROL ABSORPTION OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 1996-06-06 WO disclosed
US-5270334-A 4-methoxy-5-methyl-pyran-3-ol natural products and derivatives thereof E. R. SQUIBB & SONS, INC. (US) 1993-12-14 US disclosed
US-5248790-A Antibiotics E. R. SQUIBB & SONS, INC. (US) 1993-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144541-A1 Process for preparing alpha-halogenated retones ADH1A, ADH1C, RER1 GPR84 1884/4885SPHK1 2673/4885FFAR1 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.